Crossmark

Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study

Crossref DOI link: https://doi.org/10.1186/s12889-025-25797-0

Published Online: 2025-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Liangwen

Zhang, Yanhui

Wang, Xiaoxuan

Tang, Chaobin

Fang, Ya
Funding

Funding for this research was provided by:

Fujian Provincial Natural Science Foundation (2024J01044)

Xiamen Natural Science Foundation Project (3502Z202471020)

Xiang'an Innovation Lab Incubation Program (2023XAKJ0101032)

Funded by the National Key R&D Program (2022YFC3603004)
License Information

Text and Data Mining valid from 2025-12-04

Version of Record valid from 2026-01-07
More Information

Article History

Received: 10 October 2024

Accepted: 21 November 2025

First Online: 4 December 2025

Declarations

:

: not applicable.

: not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below